ClinicalTrials.gg
CompletedNCT01271348Updated Nov 1, 2011

Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise

A Phase 1 interventional study of Etoricoxib and placebo in Muscle Pain, sponsored by X-pert Med GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-01.

Sponsored by X-pert Med GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Myalgia with a site in Germany — 1 open to participants now, 1 under way, none of them phase 3. Myalgia · Germany.

Started
2011
the only one that year
Phase 1
2 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
X-pert Med GmbH

Among the 10 studies in Myalgia with a site in Germany, this one is the only one that started in 2011, is one of 2 in phase 1, and was the 5th registered.

Myalgia

256 studies on the registry are indexed under Myalgia; 46 are open to participants now.

Browse Myalgia studies →

Open to participants now

1 of the 10 studies in Myalgia with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 27 Myalgia studies recruiting now, 6 (22%) set no upper age limit and 20 (74%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myalgia with a site in Germany, or all of them as a file.
02

Study summary

Comparison of the effect of etoricoxib to placebo on muscle pain caused by eccentric contractions

03

Conditions studied

  • Muscle Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated prior to participation
  • Subjects in good health as determined by the Investigator
  • Age 18-40 or 50-70
  • > 20 and \< 30
  • Pain in the target muscle (thigh) during muscle contraction of at least 5 on an 11 point categorical pain rating scale
  • Willing to abstain from any physical therapy, hard physical work, exercise or sauna during the study treatment periods (Screening to Final Visit)
  • For females, subjects of (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are not allowed in this study. Female subjects, who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) are allowed for participation

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study within the last 30 days and during the study
  • Subjects who are inmates of psychiatric wards, prisons, or other state institutions
  • Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
  • Pregnancy or lactation
  • Alcohol or drug abuse
  • within the past 2 years with the exception of in situ removal of basal cell carcinoma
  • Known to etoricoxib or other NSAID´s including Cox-2, or any of their
  • Bronchospasm, acute rhinitis, nasal congestion, angioneurotic edema, urticaria or allergic reactions after taking aspirin or other NSAIDs including Cox-2 inhibitors
  • Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the musculo-sceletal system of the lower limbs
  • Pain conditions which might interfere with pain rating during the study, e.g. neuropathic pain
  • Significant neurological or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately (e.g. depressive disorders, Alzheimer's disease, schizophrenia or other psychosis), that in the investigator's opinion may affect efficacy or safety assessments or may compromise subject safety during the study
  • Heart failure ( II-IV)
  • Long term blood pressure > 140/90 mm Hg without adequate treatment
  • Peripheral arterial disease, coronary heart disease and/or cerebrovascular disease
  • History of stroke or myocardial infarction
  • changes
  • Estimated \< 60 ml/min
  • Liver dysfunction (e.g. defined by and/or AST levels above )
  • Coagulopathy or bleeding diathesis, or concomitant use of anticoagulants including low dose aspirin
  • History of pancreatitis, peptic ulcers or gastrointestinal bleedings
  • Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)
  • Any other analgesic therapy including cough and cold drugs containing analgesic properties as well as any other substance used for the treatment of pain during the study observation period (Screening to final Visit)
  • Any other drug that might alter pain perception like CNS active drugs
  • Statins within 3 months of screening and throughout the study
  • Oral anticonceptives
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Etoricoxib

    Drug: Etoricoxib

  • Placebo comparator
    Placebo tablet

    Drug: placebo

Interventions

  • Etoricoxib film tablet, 90 mg, q.d.

  • Drugplacebo

    Placebo tablet, q.d.

06

What researchers measure

Primary outcomes

  1. Pain during muscle contraction

    Time frame: 7 days

07

Study locations

1 site
  • X-pert Med GmbH
    Jena, 07745, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2011
First posted
Jan 6, 2011
Start
Jan 2011
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Nov 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01271348
Lead sponsor
X-pert Med GmbH
Responsible party
Sponsor
First posted
Jan 6, 2011
Start date
Jan 2011
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Nov 1, 2011

Study contacts

Matthias Rother, M.D.
study chair · Director Clinical Operations
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion